Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Pfizer Deal Speeds Up, Aurobindo Tangos With AstraZeneca For Branded Generics Play In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's Aurobindo Pharma is turning out to be a partner of choice for Big Pharma companies that intend to dig aggressively into emerging markets with a branded generics product portfolio

You may also be interested in...

Soriot Effect Sees AstraZeneca Selectively Scale Back Branded Generics In Emerging Markets

Leadership change is forcing the Anglo-Swedish drug giant to review its priorities in the branded generics business. AstraZeneca will invest selectively in countries where it has built a high base and shows ability to post robust growth.

With A New CEO, Will AstraZeneca Change Its Approach In Emerging Markets?

Roche’s surging growth in China could hint at what’s coming to AstraZeneca in emerging markets as Pascal Soriot, Roche’s head of pharmaceuticals, takes over at AZ.

AstraZeneca, Lilly, Novo Look To China Growth Despite Pricing Headwinds – Emerging Market Earnings Roundup (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts